Atara and Pierre Fabre's T-cell therapy gets new chance for FDA approval after twice rejected

Atara Biotherapeutics and Pierre Fabre Pharmaceuticals have received notice from the U.S. FDA that it will reconsider a previously rejected T-cell therapy.

The therapy, which had been turned down twice, may now be evaluated using data from a Phase 3 trial as the primary basis for approval.

If the FDA moves forward, the decision could revive the development program and potentially bring a new cell-based treatment to market.